Download PDF
CC BY 4.0 · Indian Journal of Neurosurgery 2023; 12(02): 137-146
DOI: 10.1055/s-0042-1743265
Original Article

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

Santosh Sharma
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
,
Kusum Mathur
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
,
Alka Mittal
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
,
Meel Mukta 
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
,
Arpita Jindal
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
,
Mukesh Kumar
1   SMS Medical College and Attached Hospital, Jaipur, Rajasthan, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction In consonance with current the World Health Organization (WHO) classification of the central nervous system (CNS) tumors (2016), histological diagnosis of gliomas should be reinforced by molecular information. This study was performed to determine the frequency of isocitrate dehydrogenase 1 (IDH1), α thalassemia/intellectual disability syndrome X-linked (ATRX), p53, and BRAF V600E mutations in different grade astrocytomas and oligodendrogliomas.

Methods Seventy-seven cases of astrocytoma and oligodendroglioma (7 pilocytic astrocytomas, 15 diffuse astrocytomas [DA], 4 anaplastic astrocytomas [AA], 29 glioblastomas [GBM], and 22 oligodendrogliomas) were analyzed using immunohistochemistry for IDH1 mutant protein, ATRX, p53, and BRAF as well as their clinicopathological features assessed.

Results All pilocytic astrocytoma and primary glioblastoma cases were negative for an IDH1 mutation. IDH1 mutation was detected in 66.7% (10/15) of DA, 50% (2/4) of AA, 20.7% (6/29) of glioblastomas, and 81.8% (18/22) of oligodendroglioma cases. Loss of nuclear ATRX expression was found in 86.7% (13/15), 75% (3/4), and 34.5% (10/29) of DA, AA, and GBM cases, respectively. All oligodendroglioma cases showed retained ATRX expression. Both markers were found statistically significant in the above tumors (p <0.05). BRAF V600E mutation was detected in a single case of pilocytic astrocytoma and pleomorphic xanthoastrocytoma as well as both cases of epithelioid glioblastoma.

Conclusions IDH1 and ATRX mutations are very common in diffuse astrocytoma and anaplastic astrocytoma, while they are rare in pilocytic astrocytoma and glioblastoma. Immunohistochemistry for IDH1 and ATRX can successfully characterize the diffuse gliomas into molecularly defined groups in the majority of the cases. BRAF V600E mutation is rare in astrocytic tumors in the Indian population.

Keywords

astrocytoma - oligodendroglioma - glioblastoma - isocitrate - dehydrogenase

Ethical Approval Statement

Ethical approval had been taken from Institutional Ethics Committee with IEC no. 299/MC/EC/2020; dated 06/06/20.


Authors' Contribution

All the authors have read & approved the manuscript.




Publication History

Article published online:
08 June 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Private Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016; 34 (04) 981-998
    CrossrefPubMedGoogle Scholar
  • 2 Ostrom QT, Gittleman H, Xu J. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-oncol 2016; 18 (suppl_5): v1-v75
    CrossrefPubMedGoogle Scholar
  • 3 McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7 (02) 418-419
    CrossrefPubMedGoogle Scholar
  • 4 Louis DN, Ohgaki H, Wiestler OD. et al; International Agency for Research on Cancer (IARC). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
    CrossrefPubMedGoogle Scholar
  • 5 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th rev. ed.. Lyon: IARC Press; 2016
    Google Scholar
  • 6 Jha P, Suri V, Sharma V. et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011; 91 (01) 385-393
    CrossrefPubMedGoogle Scholar
  • 7 Rajeswarie RT, Rao S, Nandeesh BN, Yasha TC, Santosh V. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. J Clin Pathol 2017; 71 (01) 323-329
    PubMedGoogle Scholar
  • 8 Thota B, Shukla SK, Srividya MR. et al. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol 2012; 138 (02) 177-184
    CrossrefPubMedGoogle Scholar
  • 9 Li QJ, Cai JQ, Liu CY. Evolving molecular genetics of glioblastoma. Chin Med J (Engl) 2016; 129 (04) 464-471
    CrossrefPubMedGoogle Scholar
  • 10 Santosh V, Sravya P, Gupta T. et al. ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas. Neurol India 2019; 67 (01) 173-182
    PubMedGoogle Scholar
  • 11 Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2 (09) 533-543
    CrossrefPubMedGoogle Scholar
  • 12 Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev 2013; 14 (06) 3979-3985
    CrossrefPubMedGoogle Scholar
  • 13 Chatterjee D, Radotra BD, Kumar N, Vasishta RK, Gupta SK. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int 2018; 9: 29
    CrossrefPubMedGoogle Scholar
  • 14 Sumathi V, Balakrishnan K, Krishna MSS, Maheshwari KU. Histopathological spectrum and grading of CNS tumours in tertiary centre: Case study of 83 cases. J Evid Based Med Healthcare 2016; 3: 2240-2243
    CrossrefPubMedGoogle Scholar
  • 15 Hamdani SM, Dar NQ, Reshi R. Histopathological spectrum of brain tumors: a 4-year retrospective study from a single tertiary care facility. Int J Med Sci Public Health 2019; 8: 673-676
    PubMedGoogle Scholar
  • 16 Dhar A, Bhat AR, Nizami FA. et al. Analysis of brain tumors in Kashmir Valley - A 10 year study. Bangladesh J Med Sci 2014; 13: 268-277
    CrossrefPubMedGoogle Scholar
  • 17 Ghanghoria S, Mehar R, Kulkarni CV, Mittal M, Yadav A, Patidar H. Retrospective histological analysis of CNS tumors – A 5 year study. Int J Med Sci Public Health 2014; 3: 1205-1207
    CrossrefPubMedGoogle Scholar
  • 18 Ahmed Z, Muzaffar S, Kayani N, Pervez S, Husainy AS, Hasan SH. Histological pattern of central nervous system neoplasms. J Pak Med Assoc 2001; 51 (04) 154-157
    PubMedGoogle Scholar
  • 19 Ichimura K, Pearson DM, Kocialkowski S. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol 2009; 11 (04) 341-347
    CrossrefPubMedGoogle Scholar
  • 20 Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174 (04) 1149-1153
    CrossrefPubMedGoogle Scholar
  • 21 Zou P, Xu H, Chen P. et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 2013; 8 (07) e68782
    CrossrefPubMedGoogle Scholar
  • 22 Cai J, Zhu P, Zhang C. et al. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget 2016; 7 (13) 16384-16395
    CrossrefPubMedGoogle Scholar
  • 23 Cai J, Zhang C, Zhang W. et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 2016; 3 (7-8): 258-265
    CrossrefPubMedGoogle Scholar
  • 24 Jiao Y, Killela PJ, Reitman ZJ. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3 (07) 709-722
    CrossrefPubMedGoogle Scholar
  • 25 Wiestler B, Capper D, Holland-Letz T. et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126 (03) 443-451
    CrossrefPubMedGoogle Scholar
  • 26 Gillet E, Alentorn A, Doukouré B. et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 2014; 118 (01) 131-139
    PubMedGoogle Scholar
  • 27 Appin CL, Brat DJ. Molecular genetics of gliomas. Cancer J 2014; 20 (01) 66-72
    CrossrefPubMedGoogle Scholar
  • 28 Ellison D, Kleinschmidt-DeMasters B, Park SH. Epithelioid glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. eds. WHO Classification of Tumors of the Central Nervous System, Revised 4t. France: International Agency for Research on Cancer (IARC); 2016. 50,51
    Google Scholar
  • 29 Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 2012; 5 (06) 430-436
    CrossrefPubMedGoogle Scholar